Patent Scout

Enter one target. Scout resolves its names, retrieves patent sequences and public evidence, then tells you what is supported, missing, and worth opening next.

8 automatic sources · names and aliases inferred at run time · patent-document gaps stated explicitly

Walkthrough
01Brief

Define the target

Ready

Target

We keep this spelling exactly. Canonical names and aliases are inferred only after you run.

What should count — and what should not

Plain language works: therapeutic antibody, CAR binder, exclude diagnostic reagents…

Target resolution runs first

Your spelling remains the workspace name. Scout resolves canonical identifiers and aliases as evidence metadata; it never silently renames the target.

Generated query pack

5 queries

›(target) antibody therapeutic patent

›(target) monoclonal antibody sequence SEQ ID VH VL CDR

›(target) epitope claim competition antibody blocking

Advanced: sequence tracing
Trace a sequence to possible public sourcesAuto-routed

Paste one antibody, scFv, VH/VL, or protein sequence. A durable background job checks current-task, structure, UniProt, NCBI, and public patent-protein evidence and continues if the page closes.

Protein sequence to trace (FASTA or plain text)

0 aa

Automatic routing

1 · Sequences already recalled in this Scout task
2 · RCSB PDB experimental structure sequences
3 · UniProtKB proteins and literature metadata
4 · NCBI nr protein records (rate-limited background search)
5 · NRPL2 patent proteins and publication records

Results are graded A (exact full query), B (near-exact), C (high similarity), or D (partial/weak). A hit is public similarity evidence, not automatic proof of true origin or an FTO conclusion.

Still needed: a target

Evidence readout

No target selected

Read evidence strength and coverage gaps before opening individual sources. Literature, trials, and structures are never counted as patent hits.

One run, four evidence lanes

The platform resolves the target, then searches patent sequences, therapeutics, trials, epitopes, structures, and literature in parallel.

01

Patent & sequence

02

Therapeutic & clinical

03

Epitope

04

Structure & literature

Known coverage gap

NCBI covers patent sequences. Primary patent documents still require a Lens token or later EPO / USPTO adapters; the run will label this gap explicitly.

Sequence-first evidence table
TargetSequence / SEQ IDTherapeutic AntibodyEpitope Disclosure (optional)Sourcing Basis
Run scout first; the table will be generated automatically.
Advanced: query pack5 queries
(target) antibody therapeutic patent
(target) monoclonal antibody sequence SEQ ID VH VL CDR
(target) epitope claim competition antibody blocking
(target) CAR-T scFv antigen binding domain
(target) diagnostic IHC ELISA flow clone
DocumentationEditing creates a draft

Patent families / claims

Sequence evidence

Epitope evidence

Decision / next action

Read-out checklist

Does a therapeutic antibody / CAR binder clearly appear?

Should diagnostic antibody, IHC, ELISA, or flow cytometry be excluded?

Is a full VH/VL, CDR, or SEQ ID provided?

Is a clone number given, and can the sequence be traced back?

Is an epitope residue, domain, competition antibody, or blocking pattern specified?

Is the claim a sequence, epitope, composition, or method-of-treatment claim?

Note

This produces an evidence map and R&D judgement, not an FTO or legal opinion. A real challenge / design-around strategy needs patent counsel to confirm against a claim chart.